AEZS — AEterna Zentaris Share Price
Last Trade - 00:00- $78.75m
- $9.00m
- $3.68m
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 7.32 | ||
| PEG Ratio (f) | |||
| EPS Growth (f) | |||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | |||
| Price to Tang. Book | |||
| Price to Free Cashflow | |||
| Price to Sales | |||
| EV to EBITDA | |||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | |||
| Return on Equity | |||
| Operating Margin | |||
Financial Summary
| Year End 31st Dec | Unit | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.91 | 0.92 | 26.88 | 0.53 | 3.65 | 11.86 | 10.52 | 46.29% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | -66.67 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health trend(F-Score)
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women's health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others. The Company's principal product candidates are Zoptrex (zoptarelin doxorubicin) and Macrilen (macimorelin) in oncology and endocrinology. The Company focuses on its product candidates Zoptrex and Macrilen, which are in Phase III clinical development, and on a luteinizing hormone-releasing hormone (LHRH)-disorazol Z conjugate (AEZS-138), which is in pre-clinical development in oncology and is available for partnering. The Company's direct and indirect subsidiaries include AEZS GmbH, Zentaris IVF GmbH and Aeterna Zentaris, Inc.
Directors
- Carolyn Egbert CHM
- Klaus Paulini PRE
- Leslie Auld
- Guenther Grau
- Nicola Ammer
- Matthias Gerlach VPR
- Eckhard Gunther VBD
- Gilles Gagnon DRC
- Robin Hoke
- Brent Norton
- Last Annual
- December 31st, 2020
- Last Interim
- June 30th, 2021
- Incorporated
- September 12th, 1990
- Public Since
- December 19th, 1995
- No. of Employees
- 11
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 121,297,007
- Address
- 315 Sigma Drive, SUMMERVILLE, 29486
- Web
- https://www.zentaris.com/
- Phone
- +1 8439003223
- Auditors
- PricewaterhouseCoopers LLP
Latest News for AEZS
Upcoming events for AEZS
Q3 2021 Aeterna Zentaris Inc Earnings Release
Similar to AEZS
ABEONA THERAPEUTICS ORD
NASDAQ Capital Market
ACASTI PHARMA CL A ORD
NASDAQ Capital Market
ACHIEVE LIFE SCIENCES ORD
NASDAQ Capital Market
ACURX PHARMACEUTICALS ORD
NASDAQ Capital Market
ADDEX THERAPEUTICS ADR
NASDAQ Capital Market
FAQ
As of Today at 20:44 UTC, shares in AEterna Zentaris are trading at $0.64. This share price information is delayed by 15 minutes.
Shares in AEterna Zentaris last closed at $0.64 and the price had moved by +24.56% over the past 365 days. In terms of relative price strength the AEterna Zentaris share price has underperformed the S&P500 Index by -5.5% over the past year.
There is no consensus recommendation for this security.
AEterna Zentaris does not currently pay a dividend.
AEterna Zentaris does not currently pay a dividend.
AEterna Zentaris does not currently pay a dividend.
To buy shares in AEterna Zentaris you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.64, shares in AEterna Zentaris had a market capitalisation of $78.75m.
Here are the trading details for AEterna Zentaris:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: AEZS
Based on an overall assessment of its quality, value and momentum AEterna Zentaris is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like AEterna Zentaris. Over the past six months, its share price has underperformed the S&P500 Index by -60.25%.
As of the last closing price of $0.64, shares in AEterna Zentaris were trading -24.4% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The AEterna Zentaris PE ratio based on its reported earnings over the past 12 months is 13.73. The shares last closed at $0.64.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
AEterna Zentaris' management team is headed by:
- Carolyn Egbert - CHM
- Klaus Paulini - PRE
- Leslie Auld -
- Guenther Grau -
- Nicola Ammer -
- Matthias Gerlach - VPR
- Eckhard Gunther - VBD
- Gilles Gagnon - DRC
- Robin Hoke -
- Brent Norton -
We do not have data on AEterna Zentaris' shareholders